SNGX - Soligenix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.4575
+0.0275 (+1.92%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.4300
Open1.4100
Bid1.3100 x 900
Ask1.4600 x 1000
Day's Range1.4100 - 1.4589
52 Week Range0.9100 - 3.7000
Volume1,252
Avg. Volume187,451
Market Cap25.773M
Beta0.77
PE Ratio (TTM)N/A
EPS (TTM)-1.1190
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Soligenix, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Aug. 13, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • PR Newswire7 days ago

    Soligenix Announces Recent Accomplishments And Second Quarter 2018 Financial Results

    PRINCETON, N.J., Aug. 8, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the second quarter ended June 30, 2018. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "Our primary focus remains the quality execution of our two pivotal Phase 3 clincial programs.  We are continuing to enroll patients in our double-blind, placebo-controlled Phase 3 study for the treatment of cutaneous T-cell lymphoma (CTCL) with SGX301 (synthetic hypericin), where we anticipate the interim analysis in the October 2018 timeframe and final topline results in the first half of 2019.

  • PR Newswire20 days ago

    Soligenix Announces a RiVax® Program Presentation at the 31st Annual Congress on Vaccines, Clinical Trials & B2B in Vancouver, Canada

    PRINCETON, N.J., July 26, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing potential immune correlates of protection to facilitate vaccine approval under the Food and Drug Administration (FDA) Animal Rule. The presentation will be given at the upcoming 31st Annual Congress on Vaccines, Clinical Trials & B2B Conference on July 27-28, 2018 to be held at the Executive Airport Plaza Hotel & Conference Centre, Richmond, BC, Canada.

  • PR Newswire22 days ago

    Soligenix Announces Appointment of Mark Pearson to its Board of Directors

    PRINCETON, N.J. , July 24, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...

  • PR Newswire27 days ago

    Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials

    PRINCETON, N.J., July 19, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.

  • PR Newswirelast month

    Soligenix Receives European and Canadian Patents for its Ricin Toxin Vaccine (RiVax®) Formulation

    PRINCETON, N.J., July 9, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received notice of allowance for European (application No. 12786638.2) and Canadian (application No. 2836273) patent applications further extending protection around ThermoVax® including coverage of the Company's ricin toxin vaccine, RiVax®. The issued patent is complementary to previous patents, including US patents 8,444,991 granted on May 21, 2013 and 8,808,710 granted on August 19, 2014, that include claims for methods of making stabilized vaccines and their attendant compositions.  In this new patent, the main claims cover formulations of Soligenix's proprietary thermostabilized ricin toxin vaccine, RiVax®.  The thermostable formulation of RiVax® has been shown to be stable for at least 12 months at temperatures up to 40 degrees Celsius (104 degrees Fahrenheit) and to provide 100% protection to non-human primates exposed to aerosol ricin challenge in preclinical studies.

  • Zacks Small Cap Researchlast month

    SNGX: New Financing Boosts Balance Sheet

    In early July, Soligenix (SNGX) closed an underwritten public offering of 7,766,990 shares of its common stock and warrants to purchase up to an aggregate of 3,106,796 shares of its common stock at a combined offering price of $1.03. In addition, the underwriters partially exercised the over-allotment to purchase additional warrants to purchase 466,019 shares of common stock. Gross proceeds to Soligenix from this offering were approximately $8 million.

  • PR Newswirelast month

    Soligenix Announces Closing of $8,000,000 At The Market Public Offering

    PRINCETON, N.J., July 2, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the closing of its previously announced underwritten public offering of 7,766,990 shares of its common stock and warrants to purchase up to an aggregate of 3,106,796 shares of its common stock at a combined offering price of $1.03. In addition, the underwriters partially exercised the over-allotment to purchase additional warrants to purchase 466,019 shares of common stock. Gross proceeds to Soligenix, Inc. from this offering are approximately $8,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by Soligenix, Inc.

  • PR Newswire2 months ago

    Soligenix, Inc. Prices $8,000,000 Public Offering At The Market

    PRINCETON, N.J., June 28, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock and warrants to purchase 3,106,796 shares of common stock  at a combined public offering price of $1.03 per share and warrant. The warrants will have an initial per share exercise price of $2.25, subject to customary adjustment, are exercisable immediately and will expire forty-two (42) months from the date of issuance. The gross proceeds to Soligenix, Inc. from this offering are expected to be approximately $8,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

  • PR Newswire2 months ago

    Soligenix Announces Poster at the 2018 American Society of Microbiology Microbe Conference in Atlanta, Georgia

    PRINCETON, N.J., June 4, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting preclinical and clinical data illustrating the potential utility of the Innate Defense Regulator technology in the treatment of infectious disease  at the upcoming American Society of Microbiology Microbe Conference on June 7-11, 2018 to be held at the Georgia World Congress Center, Atlanta, GA. Host-Directed Innate Defense Regulators with Preclinical and Clinical Proof of Concept attended by Dr. Oreola Donini, Chief Scientific Officer, Soligenix, Inc., on June 8, 2018 from 11:00 AM - 1:00 PM local time, Halls B2-B5.

  • Soligenix Inc’s (NASDAQ:SNGX) Shift From Loss To Profit
    Simply Wall St.3 months ago

    Soligenix Inc’s (NASDAQ:SNGX) Shift From Loss To Profit

    Soligenix Inc’s (NASDAQ:SNGX): Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company’s loss has recently broadened sinceRead More...

  • Zacks Small Cap Research3 months ago

    SNGX: ThermoVax Technology May be the Solution of Developing Heat Stable Ebola Vaccine

    Recently, Congo reported the outbreak of Ebola, with at least 32 suspected, probable or confirmed cases of the disease since April 4, including 18 deaths. The WHO is moving quickly this time, and hopes to use Ebola vaccine to stem the outbreak in Congo. The vaccine proved to be highly effective in the 2015 trial that involved more than 5,800 people, none of whom developed Ebola nine days or more after vaccination.

  • PR Newswire3 months ago

    Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results

    PRINCETON, N.J., May 11, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the first quarter ended March 31, 2018. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We are actively enrolling patients in our pivotal double-blind, placebo-controlled, multinational Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy, and expect final results in the second half of 2019.

  • PR Newswire3 months ago

    Soligenix to Present at the NYC Oncology Investor Conference 2018

    PRINCETON, N.J., May 7, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Financial Officer, Karen Krumeich, will deliver a corporate presentation at the NYC Oncology Investor Conference 2018 on Tuesday, May 8 at 2:00PM ET. The NYC Oncology Investor Conference 2018 hosted by OneMed Forum, and sponsored by the National Foundation for Cancer Research, the International Cancer Impact Fund, Klosters Innovation Partners, Wilson Sonsini Law Firm, Torreya Partners, and Marcum is the leading conference for early-stage private and public cancer investing.   For more information about the conference, please refer to the conference website.

  • PR Newswire5 months ago

    Soligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin Poisoning

    PRINCETON, N.J., March 22, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products, has granted orphan drug designation to the Company's recombinant modified ricin toxin A-chain subunit (the active pharmaceutical ingredient in RiVax®) for the prevention of ricin poisoning.  RiVax® has previously been granted orphan drug designation from the US Food and Drug Administration (FDA).

  • PR Newswire5 months ago

    Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results

    PRINCETON, N.J., March 15, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2017. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "In the third quarter of 2017, we initiated a pivotal double-blind, placebo-controlled Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy.

  • PR Newswire5 months ago

    Soligenix to Present at the 12th Annual International Partnering Conference Bio-Europe Spring

    PRINCETON, N.J., March 13, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Financial Officer, Karen Krumeich, will deliver a corporate presentation at the 12th Annual International Partnering Conference Bio-Europe Spring in Amsterdam, Wednesday, March 14 at 10:00 AM GMT. For more information about the 12th Annual International Partnering Conference Bio-Europe Spring, please refer to the conference website.

  • PR Newswire7 months ago

    Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials

    PRINCETON, N.J., Jan. 25, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.  The content of this letter is provided below.

  • ACCESSWIRE7 months ago

    Blog Exposure - Soligenix Announced Issuance of US Patent for Use of Dusquetide in Oral Mucositis

    LONDON, UK / ACCESSWIRE / January 04, 2018 / Active-Investors.com has just released a free research report on Soligenix, Inc. (NASDAQ: SNGX ). If you want access to this report all you need to do is sign ...

  • PR Newswire7 months ago

    Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis

    Soligenix has reported positive Phase 2 results with SGX942 in the treatment of oral mucositis in head and neck cancer (HNC) patients.  SGX942 at a dose of 1.5 mg/kg successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy for treatment of their HNC.  In addition to the oral mucositis findings, an increased incidence of "complete response" of tumor at both the one month and twelve month follow-up visits were observed with SGX942 treatment, as well as decreases in mortality and infection rate.  Results from the Phase 2 clinical trial have been published.

  • Zacks Small Cap Research8 months ago

    Soligenix (SNGX): Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule

    On Dec. 21, 2017, SNGX (SNGX) announced the successful identification of biomarkers for ricin toxin vaccine (RiVax®) testing. This could facilitate the approval of the testing under the FDA "Animal Rule".

  • PR Newswire8 months ago

    Soligenix Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule

    PRINCETON, N.J. , Dec. 21, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...

  • Want To Invest In Soligenix Inc (SNGX)? Here’s How It Performed Lately
    Simply Wall St.8 months ago

    Want To Invest In Soligenix Inc (SNGX)? Here’s How It Performed Lately

    After looking at Soligenix Inc’s (NASDAQ:SNGX) latest earnings update (30 September 2017), I found it helpful to revisit the company’s performance in the past couple of years and compare thisRead More...

  • PR Newswire8 months ago

    Soligenix to Receive $417,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

    PRINCETON, N.J., Nov. 30, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program.  As a result, the Company anticipates being able to transfer this credit and receive approximately $417,000 in net proceeds by year end. This competitive program enables approved technology and biotechnology businesses to sell their unused Net Operating Loss (NOL) Carryovers and unused Research and Development (R&D) Tax Credits to unaffiliated, profitable corporate taxpayers in the state of New Jersey.

  • PR Newswire9 months ago

    Soligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CA

    PRINCETON, N.J., Nov. 27, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting preclinical data from two of its biodefense development programs at the upcoming Chemical and Biological Defense Science and Technology Conference on November 28-30, 2017 to be held at the Long Beach Convention Center, Long Beach, CA. The abstract is available here.